Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06524778 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single High-dose Brachytherapy for Giant Osteosarcoma Masses

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 25, 2024 to Aug 30, 2024v3
  2. Phase: Not applicable to Phase 2
    • Primary endpoint revised
    • Eligibility criteria shortened, about 69 words
    • Secondary endpoints revised (4)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, single-arm, phase II, single-center study. Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
Trial Details
NCT Number NCT06524778
Lead Sponsor Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Conditions
(from sponsor)		 Osteosarcoma
Related terms Osteosarcoma
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov